GLP-1 clinical trials in Michigan: 18 recruiting now

18 GLP-1 clinical trials are recruiting at 27 sites in 13 cities across Michigan. Every site below is listed with its city and, where the sponsor publishes one, the number to call.

Every study recruiting in Michigan

1. A Phase 4, Prospective, Open-Label, Single Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab

   Phase 4. Run by Eli Lilly and Company. Registry number NCT06857942.

   A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people calm psoriasis.

   Who can join. Adults 18+, have psoriasis, BMI 27+.

   3 sites in Michigan

   • David Fivenson, MD, PLC, Ann Arbor. 734-222-9630
   • Great Lakes Research Group, Inc., Bay City. 989-895-9100
   • The Derm Institute of West Michigan, Caledonia. 616-326-0114

2. PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes

   Phase 4. Run by Brigham and Women's Hospital. Registry number NCT05390892.

   A study testing whether a GLP-1 medicine, semaglutide, can help people lower blood sugar.

   Who can join. Adults 40 to 80, have type 2 diabetes.

   1 site in Michigan

   • University of Michigan, Ann Arbor. 734-998-2497

3. A Phase 4, Prospective, Open-Label, Single-Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab

   Phase 4. Run by Eli Lilly and Company. Registry number NCT06864026.

   A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people ease psoriatic arthritis.

   Who can join. Adults 18+, have psoriatic arthritis, BMI 27+.

   1 site in Michigan

   • Clinical Research Institute of Michigan, LLC, Saint Clair Shores

4. A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

   Phase 3. Run by Eli Lilly and Company. Registry number NCT07165028.

   A study testing whether a GLP-1, GIP and glucagon medicine from Lilly, retatrutide, can help people reduce liver fat.

   Who can join. Adults 18+, have fatty liver disease (MASLD), BMI 25+.

   3 sites in Michigan

   • Clinical Research Institute of Michigan, LLC, Clinton Township. 586-598-3329
   • Great Lakes Research Institute, Southfield. 248-864-5242
   • Arcturus Healthcare , PLC, Troy Internal Medicine Research Division, Troy. 248-312-0025

5. A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar

   Phase 3. Run by Boehringer Ingelheim. Registry number NCT07754461.

   A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people with type 2 diabetes lower blood sugar.

   Who can join. Adults 18+, have type 2 diabetes, BMI 23+.

   3 sites in Michigan

   • Northern Pines Health Center - Buckley, Buckley. 833-602-2368
   • Revival Research Institute, LLC - Dearborn, Dearborn. 833-602-2368
   • Arcturus Healthcare - Troy Internal Medicine Research Division, Troy. 833-602-2368

6. LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced

   Phase 3. Run by Boehringer Ingelheim. Registry number NCT06632444.

   A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people reduce liver fat.

   Who can join. Adults 18+, have fatty liver disease (also called MASH or NASH) with liver scarring (fibrosis).

   2 sites in Michigan

   • Clinical Research Institute of Michigan, LLC, Clinton Township. 833-602-2368
   • West Michigan Clinical Research Center, Wyoming. 833-602-2368

7. LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

   Phase 3. Run by Boehringer Ingelheim. Registry number NCT06632457.

   A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people reduce liver fat.

   Who can join. Adults 18+, have fatty liver disease (also called MASH or NASH), BMI 25+.

   2 sites in Michigan

   • Clinical Research Institute of Michigan, LLC, Clinton Township. 833-602-2368
   • West Michigan Clinical Research Center, Wyoming. 833-602-2368

8. A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

   Phase 3. Run by Eli Lilly and Company. Registry number NCT06672549.

   A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people lose weight.

   Who can join. Children and teens 6 to 17, have obesity.

   1 site in Michigan

   • Helen Devos Childrens' Hospital - PIN, Grand Rapids

9. A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight

   Phase 3. Run by Eli Lilly and Company. Registry number NCT07202884.

   A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people reduce bladder leaks.

   Who can join. Adults 18+, women only, have stress urinary incontinence (bladder leaks), BMI 27+.

   1 site in Michigan

   • Arcturus Healthcare , PLC, Troy Internal Medicine Research Division, Troy. 248-312-0025

10. Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized Controlled Trial for Alcohol Use Disorder (CRAVE)

    Phase 3. Run by VA Office of Research and Development. Registry number NCT07218354.

    A study testing whether a GLP-1 medicine, semaglutide, can help people with alcohol use disorder drink less.

    Who can join. Adults 18 to 80, have alcohol use disorder, BMI 21+.

    1 site in Michigan

    • VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor. 734-845-5345

11. Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease

    Phase 3. Run by Eli Lilly and Company. Registry number NCT07223593.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people improve blood flow in the legs.

    Who can join. Adults 18+, have peripheral artery disease (poor blood flow in the legs), BMI 23+.

    1 site in Michigan

    • Arcturus Healthcare , PLC, Troy Internal Medicine Research Division, Troy. 248-312-0025

12. Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living

    Phase 3. Run by Kailera. Registry number NCT07284979.

    A study testing whether an investigational medicine from Kailera, KAI-9531, can help people lose weight.

    Who can join. Adults 18+, have obesity, BMI 35+.

    1 site in Michigan

    • Kailera Clinical Site, Farmington Hills

13. A Clinical Study to Compare Efficacy and Safety of Two Different Doses of CagriSema and Semaglutide in Participants With Obesity

    Phase 3. Run by Novo Nordisk A/S. Registry number NCT07564414.

    A study testing whether a study medicine from Novo Nordisk, cagrisema, can help people with type 2 diabetes lose weight.

    Who can join. Adults 18+, have obesity, BMI 35+.

    1 site in Michigan

    • Northern Pines Hlth Ctr, PC, Buckley

14. A Phase 3, Open-label Trial to Evaluate the Efficacy, Safety and Tolerability of Switching From the Glucagon-like Peptide-1

    Phase 3. Run by Amgen. Registry number NCT07575399.

    A study testing whether a study medicine from Amgen, Maridebart Cafraglutide, can help people lose weight.

    Who can join. Adults 18+, have obesity or are overweight, BMI 25+.

    1 site in Michigan

    • Arcturus Healthcare, Public Limited Company, Troy Internal Medicine Research Division, Troy

15. A Randomized, Open-label, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron

    Phase 3. Run by AstraZeneca. Registry number NCT07662213.

    A study testing whether a GLP-1 medicine, semaglutide, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18+, have type 2 diabetes, BMI 23+.

    1 site in Michigan

    • Research Site, Southfield

16. A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity

    Phase 2. Run by Eli Lilly and Company. Registry number NCT06143956.

    A study testing whether an investigational medicine from Lilly, LY3305677, can help people lose weight.

    Who can join. Adults 18 to 75, have obesity, BMI 27+.

    2 sites in Michigan

    • Headlands Research - Detroit, Southfield
    • Arcturus Healthcare , PLC, Troy Internal Medicine Research Division, Troy. 248-312-0025

17. A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living

    Phase 2. Run by Novo Nordisk A/S. Registry number NCT06717698.

    A study testing whether an investigational medicine from Novo Nordisk, NNC0519-0130, can help people with chronic kidney disease protect their kidneys.

    Who can join. Adults 18+, have chronic kidney disease, BMI 27+.

    1 site in Michigan

    • Elite Research Center, Flint

18. Tirzepatide for Partial Lipodystrophy Treatment: A New Horizon in 2024

    Phase 2. Run by University of Michigan. Registry number NCT07091734.

    A study of a GLP-1 and GIP medicine, tirzepatide, in people with partial lipodystrophy.

    Who can join. Adults 18+, have partial lipodystrophy.

    1 site in Michigan

    • University of Michigan, Ann Arbor. 734-615-0539

Source: ClinicalTrials.gov, the federal registry, read September 4, 2026. Open a study's registry record before you call: it can close to new participants at any time. GLP Chart does not enroll anyone, is not paid for clinical-trial referrals and has no relationship with any sponsor or site on this page.

John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this siteLinkedInContact